NASDAQ:PRVL - Prevail Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $24.75
  • Forecasted Upside: 7.61 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$23.00
+0.30 (1.20%)
Get New Prevail Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRVL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRVL

Analyst Price Target is $24.75
▲ +7.61% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Prevail Therapeutics in the last 3 months. The average price target is $24.75, with a high forecast of $26.00 and a low forecast of $23.00. The average price target represents a 7.61% upside from the last price of $23.00.

This chart shows the closing price for PRVL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 contributing investment analysts is to hold stock in Prevail Therapeutics. This rating has held steady since June 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/23/2020WedbushDowngradeOutperform ➝ NeutralN/A
12/16/2020Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
12/16/2020Stifel NicolausDowngradeBuy ➝ Hold$23.00Low
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ NeutralLow
12/15/2020CowenDowngradeOutperform ➝ Market PerformLow
12/15/2020Piper SandlerDowngradeOverweight ➝ NeutralHigh
11/27/2020William BlairReiterated RatingBuyLow
9/23/2020OppenheimerReiterated RatingBuy$25.00High
9/14/2020William BlairInitiated CoverageOutperform$25.00High
9/10/2020Cantor FitzgeraldInitiated CoverageOverweight$26.00High
7/29/2020OppenheimerReiterated RatingBuy$25.00Low
7/15/2020Stifel NicolausInitiated CoverageBuy$23.00Medium
5/26/2020WedbushBoost Price TargetOutperform$19.00 ➝ $22.00High
4/9/2020Piper SandlerInitiated CoverageOverweight$20.00Medium
3/26/2020WedbushReiterated RatingOutperform$20.00 ➝ $19.00Medium
3/5/2020CitigroupInitiated CoverageBuy$24.00Medium
2/18/2020OppenheimerInitiated CoverageOutperform$25.00Medium
11/12/2019CowenReiterated RatingBuyHigh
11/1/2019WedbushReiterated RatingBuy$20.00Low
9/11/2019WedbushReiterated RatingOutperformHigh
8/15/2019WedbushReiterated RatingOutperform$25.00 ➝ $20.00Low
7/15/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$20.00Low
7/15/2019WedbushInitiated CoverageOutperform ➝ Outperform$25.00High
7/15/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$15.00High
7/15/2019CowenInitiated CoverageOutperform ➝ OutperformHigh
(Data available from 7/25/2016 forward)
Prevail Therapeutics logo
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.
Read More

Today's Range

Now: $23.00
Low: $23.00
High: $23.00

50 Day Range

MA: $23.01
Low: $22.91
High: $23.20

52 Week Range

Now: $23.00
Low: $9.02
High: $23.35

Volume

N/A

Average Volume

955,800 shs

Market Capitalization

$787.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Prevail Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Prevail Therapeutics in the last twelve months: Cantor Fitzgerald, Cowen Inc, Oppenheimer Holdings Inc., Piper Sandler, Smith Barney Citigroup, Stifel Nicolaus, Wedbush, William Blair, and Zacks Investment Research.
View the latest analyst ratings for PRVL.

What is the current price target for Prevail Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Prevail Therapeutics in the last year. Their average twelve-month price target is $24.75, suggesting a possible upside of 7.6%. Cantor Fitzgerald has the highest price target set, predicting PRVL will reach $26.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $23.00 for Prevail Therapeutics in the next year.
View the latest price targets for PRVL.

What is the current consensus analyst rating for Prevail Therapeutics?

Prevail Therapeutics currently has 6 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PRVL, but not buy more shares or sell existing shares.
View the latest ratings for PRVL.

What other companies compete with Prevail Therapeutics?

How do I contact Prevail Therapeutics' investor relations team?

Prevail Therapeutics' physical mailing address is 430 East 29th Street Suite 1520, New York NY, 10016. The company's listed phone number is 917-336-9310 and its investor relations email address is [email protected] The official website for Prevail Therapeutics is www.prevailtherapeutics.com.